Treatment for pulmonary hypertension
AssigneeUnited Therapeutics Corporation
InventorsMartine A. Rothblatt, Lewis J. Rubin
Life of this patent
Estimating the term…
Abstract
One embodiment relates to a method of treating pulmonary hypertension based upon co-administering to a subject in need thereof a pharmaceutically effective amount of an oral therapeutic agent for treating pulmonary hypertension and a pharmaceutically effective amount of an inhaled therapeutic agent for treating pulmonary hypertension. The benefit of the co-administration of these agents is to eliminate or reduce one or more side effects associated with mono-therapy of either agent, as well as one or more side effects associated with other administration routes such as subcutaneous or intravenous administration.
Claims8
A method of treating pulmonary hypertension comprising co-administering to a subject in need thereof a pharmaceutically effective amount of an oral therapeutic agent for treating pulmonary hypertension and a pharmaceutically effective amount of an inhaled therapeutic agent for treating pulmonary hypertension, wherein the oral therapeutic agent comprises beraprost or a pharmaceutically acceptable salt thereof and the inhaled therapeutic agent comprises treprostinil or a pharmaceutically acceptable salt thereof.
A method of reducing a side effect of a pulmonary hypertension treatment administered by subcutaneous or intravenous delivery, comprising co-administering to a subject in need thereof a pharmaceutically effective amount of an oral therapeutic agent for treating pulmonary hypertension and a pharmaceutically effective amount of an inhaled therapeutic agent for treating pulmonary hypertension, wherein the oral therapeutic agent comprises beraprost or a pharmaceutically acceptable salt thereof and the inhaled therapeutic agent comprises treprostinil or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.